Glaukos (NYSE:GKOS) Announces Quarterly Earnings Results, Misses Expectations By $0.02 EPS

Glaukos (NYSE:GKOS) released its quarterly earnings results on Thursday. The medical instruments supplier reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.38) by ($0.02), Zacks reports. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%.

Glaukos Price Performance

Shares of NYSE:GKOS traded down $2.61 on Thursday, reaching $157.97. 1,064,575 shares of the company were exchanged, compared to its average volume of 568,425. The company has a current ratio of 5.54, a quick ratio of 4.71 and a debt-to-equity ratio of 0.19. Glaukos has a 1-year low of $83.90 and a 1-year high of $163.71. The firm has a market cap of $8.71 billion, a price-to-earnings ratio of -52.31 and a beta of 1.04. The company has a 50-day moving average of $152.65 and a 200-day moving average of $139.03.

Wall Street Analysts Forecast Growth

Several analysts recently commented on GKOS shares. BTIG Research upped their price target on shares of Glaukos from $140.00 to $149.00 and gave the company a “buy” rating in a research report on Tuesday, November 26th. Wells Fargo & Company upped their price target on shares of Glaukos from $145.00 to $153.00 and gave the company an “overweight” rating in a research report on Wednesday, December 11th. Piper Sandler reiterated an “overweight” rating and issued a $180.00 price target (up previously from $140.00) on shares of Glaukos in a research report on Monday, January 27th. Mizuho upgraded shares of Glaukos from a “neutral” rating to an “outperform” rating and upped their price objective for the stock from $140.00 to $200.00 in a research report on Wednesday. Finally, JPMorgan Chase & Co. upped their price objective on shares of Glaukos from $130.00 to $145.00 and gave the stock an “overweight” rating in a research report on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, one has assigned a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $159.42.

Insider Transactions at Glaukos

In related news, Director Gilbert H. Kliman sold 10,000 shares of the stock in a transaction dated Friday, December 20th. The shares were sold at an average price of $150.28, for a total value of $1,502,800.00. Following the sale, the director now directly owns 32,336 shares of the company’s stock, valued at approximately $4,859,454.08. This represents a 23.62 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, insider Tomas Navratil sold 3,416 shares of the stock in a transaction dated Friday, February 14th. The shares were sold at an average price of $147.14, for a total transaction of $502,630.24. Following the completion of the sale, the insider now directly owns 72,437 shares in the company, valued at approximately $10,658,380.18. The trade was a 4.50 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 18,744 shares of company stock valued at $2,792,151 in the last ninety days. 6.40% of the stock is currently owned by company insiders.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.